DOCK3 and Cognitive impairment: In both crude and model 1, compared with the Q1 group, patients in Q4 had a higher risk of moderate-severe cognitive impairment at 1 month (adjusted OR = 2.36, 95% CI 1.09–5.12, P = 0.030 for MMSE; OR = 3.34, 95% CI 1.64–6.80, P = 0.001 for MoCA), whereas the direction of the relationship between SUA and incidence of moderate-severe cognitive impairment changed once eGFR was introduced into the model (OR = 0.64, 95% CI 0.25–1.62, P = 0.350 for MMSE; OR = 0.67, 95% CI 0.28–1.64, P = 0.384 for MoCA in Model 2).